B6 cd45

C57BL/6 (B6) mice homozygous for loxP-flanked caspase-8 allele (Casp8^fl/fl) [11 (link)] were crossed with mice expressing Cre under control of murine lysozyme M gene promoter (Cre^LysM; The Jackson Laboratory, Bar Harbor, ME, USA), generating Cre^LysMCasp8^fl/fl mice. Cre^LysMCasp8^fl/fl mice were crossed with RIPK3^−/− (Genentech, South San Francisco, CA, USA) to generate RIPK3^−/−Cre^LysMCasp8^fl/fl mice. OT-II/RAG^−/− and B6.CD45.1 were purchased from The Jackson Laboratory. B6.CD45.1/2 mice were generated from a cross of B6 (The Jackson Laboratory) and B6.CD45.1 mice. Female mice were used in all studies. Proteinuria was assessed using Uristix reagent strips (Siemens Healthcare Diagnostics, Tarrytown, NY, USA). Transnetyx (Cordova, TN, USA) performed all genotyping of mice. All animal experiments were approved by the Northwestern University Institutional Animal Care and Use Committee.

B6 (CD45.2) and B6-Ly5.1 (CD45.1) mice were purchased from Jackson Laboratory. The MycTg mice^{25 (link)}, in which a loxP-flanked ‘stop’ cassette precedes a human MYC cDNA inserted into the Rosa-26 locus, were purchased from Jackson Laboratory (Stock No: 020458) and crossed with FoxN1Cre mice that were a gift from G.Hollander^{24 (link)}. Myc-GFP mice^{45 (link)}, with Myc fused to GFP in the N-terminus, were purchased from Jackson Laboratory (Stock No: 21935).
Krt5-CreERT2 knock-in mice^{31 (link)} were purchased from Jackson Laboratory (Stock No: 029155). Rag2-EGFP mice^{46 (link)} were purchased from Jackson Laboratory (Stock No: 005688). Mice described as newborn were 0–2 days in age and of either sex. Mice described as adult for flow cytometry/sequencing experiments were 4–6 weeks of age and of either sex (unless otherwise stated). Aged mice were between 18 and 21 months of age. The ages of embryonic mice are specified with E0.5 being noon of the day of the discovered plug. Animal procedures were approved by relevant National Institutes of Health Animal Care and Use Committees.

All animal use and care were performed according to protocols approved by the Animal Research Committee, Graduate School of Medicine, Kyoto University, and we complied with all the ethical regulations. All mice were housed at the Institute of Laboratory Animals, Kyoto University, under specific pathogen-free conditions, and all animal experiments were conducted in accordance with the guidelines for animal experiments at Kyoto University and RIKEN Kobe Branch. C57BL/6 (B6) mice were obtained from SLC, Japan. Cpdm mice were described previously^{7 (link)}. Rag2^−/− mice were obtained from the Central Institute of Experimental Animals, Japan. TNFα^−/− (Stock number: 003008) and B6 (CD45.1) (Stock number: 002014) mice were obtained from the Jackson Laboratory. Lck-Cre (Model number: 4197) transgenic mice were obtained from Taconic. β5t-iCre knock-in mice and Foxp3-YFP/iCre knock-in mice were kindly provided by Yousuke Takahama (University of Tokushima, Japan) and Alexander Y. Rudensky (Memorial Sloan Kettering Cancer Center, USA), respectively^{42 (link),43 (link)}. Ripk3^−/− mice were kindly provided by Vishva Dixit (Genentech, USA)^{44 (link)}. K5-Cre mice were obtained from CARD-Kumamoto University, Japan^{45 (link)}. Sharpin conditional KO, HOIP conditional KO, and Sharpin conditional transgenic mice were generated in-house, and are available from RIKEN BRC, Japan.

C57BL/6 were purchased from Taconic Biosciences and Jackson Laboratory. Rag2^-/- and Batf3^-/- mice were purchased from Jackson Laboratory and bred in-house. B6 CD45.1 were purchased from Jackson Laboratory. All mice were housed and bred under specific pathogen-free (SPF) conditions at the Koch Institute for Integrative Cancer Research Building animal facility. For all studies, mice were gender-matched and age-matched to 6–12 weeks old at the start of experiments. All experimental animal procedures were approved by the Committee on Animal Care (CAC/IACUC) at MIT.